Metis Global Partners LLC Sells 810 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Metis Global Partners LLC lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 5,497 shares of the biopharmaceutical company’s stock after selling 810 shares during the quarter. Metis Global Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $2,886,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Activest Wealth Management raised its holdings in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 21 shares during the last quarter. Costello Asset Management INC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at about $27,000. Saudi Central Bank bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $31,000. Finally, Colonial Trust Advisors purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $32,000. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In related news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 7.02% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on REGN shares. Morgan Stanley reduced their price target on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Guggenheim boosted their target price on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Weiss Ratings reissued a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 8th. Rothschild & Co Redburn assumed coverage on Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They issued a “buy” rating and a $890.00 price target for the company. Finally, Bank of America lifted their price target on shares of Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an “underperform” rating in a report on Wednesday, October 29th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $796.57.

Regeneron Pharmaceuticals Trading Up 1.6%

NASDAQ REGN opened at $657.53 on Monday. The firm has a market capitalization of $69.69 billion, a PE ratio of 15.75, a P/E/G ratio of 2.03 and a beta of 0.31. The stock’s 50 day moving average is $588.03 and its 200 day moving average is $567.90. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $834.42. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter in the prior year, the company earned $12.46 earnings per share. The firm’s quarterly revenue was up .9% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.